secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2021-11-03T23:59:59+00:00
Accession:  0001193805-21-001525
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics appoints Dr. Urte Gayko to Board of Directors
-----------------------------------------------------------------

- Dr. Urte Gayko appointed to Summit's Board effective Nov 3, 2021; will serve on Nominating and Corporate Governance Committee.
- Gayko is SVP of Drug Development & Regulatory Affairs at Nektar Therapeutics; previously Global Head of Regulatory at Pharmacyclics.
- Over 20 years experience in regulatory and clinical development across Amgen, AbbVie, and biotech; PhD in molecular/cellular biology from Harvard.
- She received an option grant under Summit's non-employee director compensation policy; also standard indemnification agreement.
- Board determined Gayko qualifies as independent director under Nasdaq listing rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000119380521001525/0001193805-21-001525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000119380521001525/e621052_8k-summit.htm
  HTML page:      https://secwatch.observer/filing/0001193805-21-001525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer